According to the presented data, among the participants in the Telitacicept 240 mg group, 98.1% of the patients demonstrated a ≥ 3-point reduction in Myasthenia Gravis Activities ... subjective ...

US biotech Cartesian Therapeutics (Nasdaq: RNAC) has reported that patients with generalized myasthenia gravis (gMG) continued to experience lasting symptom relief 12 months after treatment with its ...

There is no guarantee that they will become commercially available for the use(s) under investigation. * Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG and likely not in need v of a ...

Participants treated with Descartes-08 were observed to have an average Quantitative Myasthenia Gravis Score (QMG) reduction of 4.8 (±1.7) points at month 4, which deepened through month 12 (6.0 ...

Descartes-08 represents a flagship advancement in Cartesian’s mission to transform the treatment landscape for autoimmune diseases, with this latest data reinforcing its potential as a safe and ...

Some patients have follow-up data extending to 128 weeks. 1 b. QMG (Quantitative Myasthenia Gravis) is a 13-item assessment by a clinician that quantifies MG disease severity. The total QMG score ...

anti-LRP4+) adults with generalised myasthenia gravis (gMG). 1, 2 Patients treated with nipocalimab plus standard of care (SOC) maintained improvements in their MG-ADL b and QMG c scores over 84 weeks ...

anti-LRP4+) adults with generalised myasthenia gravis (gMG). 1, 2 Patients treated with nipocalimab plus standard of care (SOC) maintained improvements in their MG-ADL b and QMG c scores over 84 ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to ...

1 Antozzi, C et al., Long-Term Safety and Efficacy of Nipocalimab in Generalized Myasthenia Gravis: Vivacity-MG3 Open-Label Extension Phase Results. Abstract #022 for poster presentation at 2025 ...